Last reviewed · How we verify
Matching Placebo to Fidaxomicin
Matching Placebo to Fidaxomicin is a Small molecule drug developed by Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). It is currently in Phase 3 development for Matching placebo control for fidaxomicin clinical trials (likely Clostridioides difficile infection).
This is a placebo formulation designed to match the appearance and administration characteristics of fidaxomicin for blinded clinical trial comparison.
This is a placebo formulation designed to match the appearance and administration characteristics of fidaxomicin for blinded clinical trial comparison. Used for Matching placebo control for fidaxomicin clinical trials (likely Clostridioides difficile infection).
At a glance
| Generic name | Matching Placebo to Fidaxomicin |
|---|---|
| Sponsor | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Matching placebos are inert formulations used in randomized controlled trials to maintain blinding and ensure valid comparison between active drug and control groups. This particular placebo is manufactured to be indistinguishable from fidaxomicin (a narrow-spectrum antibiotic that inhibits bacterial RNA polymerase) in terms of appearance, taste, and physical properties, allowing patients and investigators to remain unaware of treatment assignment.
Approved indications
- Matching placebo control for fidaxomicin clinical trials (likely Clostridioides difficile infection)
Common side effects
Key clinical trials
- A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System (PHASE4)
- Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) (PHASE3)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching Placebo to Fidaxomicin CI brief — competitive landscape report
- Matching Placebo to Fidaxomicin updates RSS · CI watch RSS
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI
Frequently asked questions about Matching Placebo to Fidaxomicin
What is Matching Placebo to Fidaxomicin?
How does Matching Placebo to Fidaxomicin work?
What is Matching Placebo to Fidaxomicin used for?
Who makes Matching Placebo to Fidaxomicin?
What development phase is Matching Placebo to Fidaxomicin in?
Related
- Manufacturer: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Matching placebo control for fidaxomicin clinical trials (likely Clostridioides difficile infection)
- Compare: Matching Placebo to Fidaxomicin vs similar drugs
- Pricing: Matching Placebo to Fidaxomicin cost, discount & access